Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPS101A Gene Therapy in Advanced Parkinson's Disease
NCT07371338Phase 1Recruiting
- Sponsor
- Innopeutics
- Start
- May 2026
- Primary completion
- Jun 2028
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label trial of IPS101A in Parkinson's disease (PD) (2 arms), sponsored by Innopeutics. Primary endpoints: Dose-Limiting Toxicity at 8 weeks, Adverse Events at 52 weeks and 2 more. Started May 2026; status: recruiting.
02
Drugs
IPS101A
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07371338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371338.